Key references: Surgical prophylaxis for skin and soft tissue surgery
Alster TS, Nanni CA. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Dermatol Surg 1999;25(3):242–6. https://www.ncbi.nlm.nih.gov/pubmed/10193975
Amici JM, Rogues AM, Lasheras A, Gachie JP, Guillot P, Beylot C, et al. A prospective study of the incidence of complications associated with dermatological surgery. Br J Dermatol 2005;153(5):967–971 .[PubMed]
Beeson WH, Rachel JD. Valacyclovir prophylaxis for herpes simplex virus infection or infection recurrence following laser skin resurfacing. Dermatol Surg 2002;28(4):331–6. https://www.ncbi.nlm.nih.gov/pubmed/11966791
Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-1) prophylaxis after facial resurfacing: A randomized clinical trial of dosing regimens. Dermatol Surg 2000;26(1):50–4. https://www.ncbi.nlm.nih.gov/pubmed/10632686
Heal CF, Buettner PG, Drobetz H. Risk factors for surgical site infection after dermatological surgery. Int J Dermatol 2012;51(7):796–803 .[PubMed]
Kulichová D, Geimer T, Mühlstädt M, Ruzicka T, Kunte C. Surgical site infections in skin surgery: a single center experience. J Dermatol 2013;40(10):779–785 .[PubMed]
Stankiewicz M, Coyer F, Webster J, Osborne S. Incidence and predictors of lower limb split-skin graft failure and primary closure dehiscence in day-case surgical patients. Dermatol Surg 2015;41(7):775–783 .[PubMed]
Wall SH, Ramey SJ, Wall F. Famciclovir as antiviral prophylaxis in laser resurfacing procedures. Plast Reconstr Surg 1999;104(4):1103–8; discussion 9. https://www.ncbi.nlm.nih.gov/pubmed/10654754